These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 27431353)

  • 1. New Treatment Guidelines for Sjögren's Disease.
    Vivino FB; Carsons SE; Foulks G; Daniels TE; Parke A; Brennan MT; Forstot SL; Scofield RH; Hammitt KM
    Rheum Dis Clin North Am; 2016 Aug; 42(3):531-51. PubMed ID: 27431353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Guidelines for Rheumatologic Manifestations of Sjögren's Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain.
    Carsons SE; Vivino FB; Parke A; Carteron N; Sankar V; Brasington R; Brennan MT; Ehlers W; Fox R; Scofield H; Hammitt KM; Birnbaum J; Kassan S; Mandel S
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):517-527. PubMed ID: 27390247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.
    Bowman SJ; Everett CC; O'Dwyer JL; Emery P; Pitzalis C; Ng WF; Pease CT; Price EJ; Sutcliffe N; Gendi NST; Hall FC; Ruddock SP; Fernandez C; Reynolds C; Hulme CT; Davies KA; Edwards CJ; Lanyon PC; Moots RJ; Roussou E; Giles IP; Sharples LD; Bombardieri M
    Arthritis Rheumatol; 2017 Jul; 69(7):1440-1450. PubMed ID: 28296257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
    Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SER recommendations on the use of biological drugs in primary Sjögren's syndrome.
    Andréu Sánchez JL; Fernández Castro M; Del Campo Fontecha PD; Corominas H; Narváez García FJ; Gómez de Salazar JR; Rua-Figueroa Í; Abad Hernández MÁ; Álvarez Rivas MN; Montes JDP; Francisco Hernández FM; Gantes Pedraza MÁ; Greco Merino MG; Hernández MV; Navarro Compán MV; Solarte JAP; Romero Bueno FI; Park HS; Sivera Mascaró F
    Reumatol Clin (Engl Ed); 2019; 15(6):315-326. PubMed ID: 30683506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
    Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
    Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Biologics in Sjögren's Syndrome.
    Nocturne G; Cornec D; Seror R; Mariette X
    Rheum Dis Clin North Am; 2016 Aug; 42(3):407-17. PubMed ID: 27431344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Sjögren's syndrome: current therapy and future directions.
    Fox RI; Fox CM; Gottenberg JE; Dörner T
    Rheumatology (Oxford); 2021 May; 60(5):2066-2074. PubMed ID: 31034046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies.
    Ramos-Casals M; Brito-Zerón P; Bombardieri S; Bootsma H; De Vita S; Dörner T; Fisher BA; Gottenberg JE; Hernandez-Molina G; Kocher A; Kostov B; Kruize AA; Mandl T; Ng WF; Retamozo S; Seror R; Shoenfeld Y; Sisó-Almirall A; Tzioufas AG; Vitali C; Bowman S; Mariette X;
    Ann Rheum Dis; 2020 Jan; 79(1):3-18. PubMed ID: 31672775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy.
    Demarchi J; Papasidero S; Medina MA; Klajn D; Chaparro Del Moral R; Rillo O; Martiré V; Crespo G; Secco A; Catalan Pellet A; Amitrano C; Crow C; Asnal C; Pucci P; Caeiro F; Benzanquen N; Pirola JP; Mayer M; Zazzetti F; Velez S; Barreira J; Tamborenea N; Santiago L; Raiti L
    Clin Rheumatol; 2017 Nov; 36(11):2455-2460. PubMed ID: 28913747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Issues related to clinical trials of oral and biologic disease-modifying agents for Sjögren's syndrome.
    Carsons SE
    Rheum Dis Clin North Am; 2008 Nov; 34(4):1011-23, x. PubMed ID: 18984419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The management of Sjögren's syndrome: British Society for Rheumatology guideline scope.
    Price E; Allen A; Rauz S; Tappuni A; Sutcliffe N; Bombardieri M; Carty S; Ciurtin C; Crampton B; Duncalfe L; Fisher B; Glennon P; Hackett KL; Larkin G; Ng WF; Ramanan AV; Rassam S; Walsh SB; Bowman S
    Rheumatology (Oxford); 2021 May; 60(5):2122-2127. PubMed ID: 33331922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of patients presenting with Sjogren's syndrome.
    Venables PJ
    Best Pract Res Clin Rheumatol; 2006 Aug; 20(4):791-807. PubMed ID: 16979538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recognition and management of Sjögren's syndrome: strategies for the advanced practice nurse.
    Vale DL
    Nurs Clin North Am; 2000 Mar; 35(1):267-78. PubMed ID: 10673580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stumbles in Sjögren's syndrome drug development: where to look for the next big leap?
    Verstappen GM; Kroese FGM; Bootsma H
    Expert Rev Clin Immunol; 2020 Nov; 16(11):1043-1045. PubMed ID: 33196342
    [No Abstract]   [Full Text] [Related]  

  • 16. Sjögren's syndrome: managed care data from a large United States population highlight real-world health care burden and lack of treatment options.
    Birt JA; Tan Y; Mozaffarian N
    Clin Exp Rheumatol; 2017; 35(1):98-107. PubMed ID: 27749234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis.
    Wang SQ; Zhang LW; Wei P; Hua H
    BMC Musculoskelet Disord; 2017 May; 18(1):186. PubMed ID: 28499370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sjögren's syndrome: evidence- and practice-based guidance.
    Marinho A; Delgado Alves J; Fortuna J; Faria R; Almeida I; Alves G; Araújo Correia J; Campar A; Brandão M; Crespo J; Marado D; Matos-Costa J; Oliveira S; Salvador F; Santos L; Silva F; Fernandes M; Vasconcelos C
    Front Immunol; 2023; 14():1117699. PubMed ID: 37138867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sjögren Syndrome: Why Do Clinical Trials Fail?
    Fox RI; Fox CM
    Rheum Dis Clin North Am; 2016 Aug; 42(3):519-30. PubMed ID: 27431352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment strategies for Sjögren's syndrome with childhood onset: a systematic review of the literature.
    Doolan G; Faizal NM; Foley C; Al-Obaidi M; Jury EC; Price E; Ramanan AV; Lieberman SM; Ciurtin C
    Rheumatology (Oxford); 2022 Mar; 61(3):892-912. PubMed ID: 34289032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.